Growth Metrics

Amneal Pharmaceuticals (AMRX) Accumulated Expenses (2018 - 2019)

Amneal Pharmaceuticals has reported Accumulated Expenses over the past 2 years, most recently at $29.0 million for Q4 2019.

  • For Q4 2019, Accumulated Expenses fell 62.41% year-over-year to $29.0 million; the TTM value through Dec 2019 reached $29.0 million, down 62.41%, while the annual FY2019 figure was $29.0 million, 62.41% down from the prior year.
  • Accumulated Expenses for Q4 2019 was $29.0 million at Amneal Pharmaceuticals, down from $77.1 million in the prior quarter.
  • Over five years, Accumulated Expenses peaked at $77.1 million in Q4 2018 and troughed at $29.0 million in Q4 2019.